CELYAD ONCOLOGY (CYAD.BR) Stock Income Statement
EBR:CYAD - Euronext Brussels - BE0974260896 - Common Stock - Currency: EUR
| TTM (2024-6-30) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 72.00K | 102.00K | 0.00 | 0.00 | 5.00K | |||
| Cost Of Goods | 34.00K | 69.00K | 0.00 | 0.00 | 0.00 | |||
| Gross Profit | 38.00K | 33.00K | 0.00 | 0.00 | 5.00K | |||
| Operating Expenses | 7.83M | 9.58M | 5.77M | 26.39M | 16.98M | |||
| Research and Development | 3.47M | 3.88M | 17.70M | 19.50M | 20.01M | |||
| Selling, General, and Administrative Expenses | 4.10M | 5.96M | 10.34M | 9.66M | 8.99M | |||
| Operating Income | -7.79M | -9.54M | -5.77M | -26.39M | -16.98M | |||
| Interest Income/Expense | -20.00K | -41.00K | 1.00K | -206.00K | -365.00K | |||
| Other Income/Expense | N/A | -13.00K | -14.00K | 95.00K | 148.00K | |||
| Non Recurring Items | N/A | 1.09M | -35.08M | -1.00K | -10.00K | |||
| Income Before Taxes | -7.82M | -8.51M | -40.87M | -26.50M | -17.20M | |||
| Income Tax | -63.00K | -63.00K | 65.00K | 10.00K | 0.00 | |||
| Net Income | -7.75M | -8.45M | -40.94M | -26.51M | -17.20M | |||
| EBITDA | -7.17M | -8.75M | -4.33M | -24.87M | -15.14M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.24 | -0.33 | -1.81 | -1.70 | -1.23 | |||
| Statistics | ||||||||
| Gross Profit Margin | 52.78% | 32.35% | N/A | N/A | 100.00% | |||
| Profit Margin | -10766.67% | -8282.35% | N/A | N/A | -344080.00% | |||
| Operating Profit Margin | -10826.39% | -9356.86% | N/A | N/A | -339540.00% | |||
All data in EUR